Dosage of Prazine 50mg in details
Prazine 50mg Dosage
Applies to the following strengths: 50 mg; 25 mg; 50 mg/mL; 25 mg/mL
Usual Adult Dose for:
- Agitated State
Usual Pediatric Dose for:
- Psychosis
Additional dosage information:
- Dose Adjustments
- Dialysis
- Other Comments
Usual Adult Dose for Agitated State
IM: 50-150 mg, depending on the degree of severity.
May give additional doses in 30 minutes up to a total of 300 mg. Once control is obtained, administer orally.
Oral or IM: 10-200 mg every 4-6 hours.
Usual Pediatric Dose for Psychosis
Child > 12 years:
Oral or IM: 10-25 mg every 4-6 hours.
Dose Adjustments
In less severe disturbances, adjust dose downward.
Dialysis
Prazine 50mg is not dialyzable.
Other Comments
The total daily dose should not exceed 1000 mg.
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
Medical Disclaimer
More about Prazine 50mg
- Prazine 50mg Side Effects
- During Pregnancy
- Drug Interactions
- 1 Review
- Drug class: phenothiazine antiemetics
Related treatment guides
- Agitated State
- Psychosis
- Schizophrenia
Prazine 50mg interactions
The concomitant administration of this product with other medication such as central nervous system depressants (including alcohol and anaesthetics) or antihypertensives, anticholinergic or dopaminergic drugs may result in accentuation of their effects, while potentiation of action may also occur with monoamine oxidase inhibitors, antidepressants and analgesics. Prazine 50mg may impair the effects of anticonvulsants. Prazine 50mg may affect the control of diabetes. Undesirable anticholinergic effects can be enhanced by anti-parkinson or other anticholinergic drugs.
The concomitant administration of this product with myelosuppressive drugs (carbamazepine, co-trimoxazole, chloramphenicol, sulphonamides, pyralizone analgesics (e.g. azapropazone), penicillamine and cytotoxics) increases the risk of toxicity.
Lithium administration will result in an increased risk of extrapyramidal effects and the possibility of neurotoxicity.
Sotalol administration will result in an increased risk of ventricular arrhythmia.
Concomitant use of Prazine 50mg with drugs known to prolong the QT interval may increase the risk of ventricular arrhythmias, including torsade de pointes. Therefore concomitant use of these products is not recommended. Examples include certain antiarrhythmics, such as those of Class 1A (such as quinidine, disopyramide and procainamide) and Class III (such as amiodarone, sotalol and dofetilide), certain antimicrobials (sparfloxacin, moxifloxacin, erythromycin IV), tricyclic antidepressants (such as amitriptyline), certain tetracyclic antidepressants (such as maprotiline), other neuroleptics (e.g. phenothiazines, pimozide, sertindole and haloperidol), certain antihistamines (such as terfenadine), cisapride, bretylium and certain antimalarials such as quinine and mefloquine. This list is not comprehensive.
Concurrent use of drugs causing electrolyte imbalance is not recommended. Diuretics, in particular those causing hypokalemia, should be avoided but, if necessary, potassium-sparing diuretics are preferred.
References
- FDA/SPL Indexing Data. "O9M39HTM5W: The UNique Ingredient Identifier (UNII) is an alphanumeric substance identifier from the joint FDA/USP Substance Registration System (SRS).". https://www.fda.gov/ForIndustry/Data... (accessed September 17, 2018).
- MeSH. "Dopamine Antagonists". https://www.ncbi.nlm.nih.gov/mesh/68... (accessed September 17, 2018).
- European Chemicals Agency - ECHA. "Promazine: The information provided here is aggregated from the "Notified classification and labelling" from ECHA's C&L Inventory. ". https://echa.europa.eu/information-o... (accessed September 17, 2018).
Reviews
The results of a survey conducted on ndrugs.com for Prazine 50mg are given in detail below. The results of the survey conducted are based on the impressions and views of the website users and consumers taking Prazine 50mg. We implore you to kindly base your medical condition or therapeutic choices on the result or test conducted by a physician or licensed medical practitioners.User reports
Consumer reported frequency of use
No survey data has been collected yetConsumer reported doses
No survey data has been collected yetConsumer reviews
There are no reviews yet. Be the first to write one! |
Information checked by Dr. Sachin Kumar, MD Pharmacology
